These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17976987)

  • 1. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors.
    Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
    Franciskovich JB; Masters JJ; Tinsley JM; Craft TJ; Froelich LL; Gifford-Moore DS; Klimkowski VJ; Smallwood JK; Smith GF; Smith T; Towner RR; Weir LC; Wiley MR
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4838-41. PubMed ID: 16140530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
    Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
    J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of glycine and related amino acid-based factor Xa inhibitors.
    Kohrt JT; Filipski KJ; Cody WL; Bigge CF; La F; Welch K; Dahring T; Bryant JW; Leonard D; Bolton G; Narasimhan L; Zhang E; Peterson JT; Haarer S; Sahasrabudhe V; Janiczek N; Desiraju S; Hena M; Fiakpui C; Saraswat N; Sharma R; Sun S; Maiti SN; Leadley R; Edmunds JJ
    Bioorg Med Chem; 2006 Jul; 14(13):4379-92. PubMed ID: 16529937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-phenylglycinol-derived non-covalent factor Xa inhibitors: effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity.
    Klimkowski VJ; Watson BM; Wiley MR; Liebeschuetz J; Franciskovich JB; Marimuthu J; Bastian JA; Sall DJ; Smallwood JK; Chirgadze NY; Smith GF; Foster RS; Craft T; Sipes P; Chastain M; Sheehan SM
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5801-5. PubMed ID: 17881231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of acylguanidine FXa inhibitors.
    O'Connor SP; Atwal K; Li C; Liu EC; Seiler SM; Shi M; Shi Y; Stein PD; Wang Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4696-9. PubMed ID: 18644722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.
    Zbinden KG; Anselm L; Banner DW; Benz J; Blasco F; Décoret G; Himber J; Kuhn B; Panday N; Ricklin F; Risch P; Schlatter D; Stahl M; Thomi S; Unger R; Haap W
    Eur J Med Chem; 2009 Jul; 44(7):2787-95. PubMed ID: 19200624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
    Chan C; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chung CW; Convery MA; Hamblin JN; Johnstone L; Kelly HA; Kleanthous S; Patikis A; Patel C; Pateman AJ; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE; Whitworth C; Young RJ; Zhou P
    J Med Chem; 2007 Apr; 50(7):1546-57. PubMed ID: 17338508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
    Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ
    Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.
    Jia ZJ; Wu Y; Huang W; Zhang P; Clizbe LA; Goldman EA; Sinha U; Arfsten AE; Edwards ST; Alphonso M; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1221-7. PubMed ID: 14980670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor.
    Kohrt JT; Bigge CF; Bryant JW; Casimiro-Garcia A; Chi L; Cody WL; Dahring T; Dudley DA; Filipski KJ; Haarer S; Heemstra R; Janiczek N; Narasimhan L; McClanahan T; Peterson JT; Sahasrabudhe V; Schaum R; Van Huis CA; Welch KM; Zhang E; Leadley RJ; Edmunds JJ
    Chem Biol Drug Des; 2007 Aug; 70(2):100-12. PubMed ID: 17683371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
    Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
    Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
    Bauer SM; Goldman EA; Huang W; Su T; Wang L; Woolfrey J; Wu Y; Zuckett JF; Arfsten A; Huang B; Kothule J; Lin J; May B; Sinha U; Wong PW; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4045-50. PubMed ID: 15225723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.
    Qiao JX; Chang CH; Cheney DL; Morin PE; Wang GZ; King SR; Wang TC; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4419-27. PubMed ID: 17588746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
    Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
    J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.